Full Year Trading Update

Summary by AI ^BETAClose X

Eco Animal Health Group plc announced a strong full-year trading update for the year ending 31 March 2026, with expected revenue growth of approximately 8% year-on-year, surpassing market expectations of £83.5 million and building on the prior year's £79.6 million. This growth, particularly in North and Latin America, coupled with improved gross margins driven by better pricing and cost of goods, is projected to result in a material increase in adjusted EBITDA over the previous year's £7.3 million, also exceeding market expectations of £7.6 million.

Disclaimer*

Eco Animal Health Group PLC

19 March 2026

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

19 March 2026

ECO Animal Health Group plc

("ECO" or the "Company")

Full Year Trading Update

Continued strong momentum in H2 with improved margins outperforming market expectations

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the following unaudited trading update for the year ending 31 March 2026.

As previously announced, trading in the first half of this financial year was significantly stronger compared to the same period last year. This trend has continued to year end with an expected year-on-year increase in revenue of c.8%, slightly ahead of market expectations¹ (2025: £79.6 million). Revenue growth has been particularly strong in North America and Latin America, despite currency headwinds and tariff challenges.

The Company also expects to report improved gross margins for the year, primarily driven by improved product pricing and cost of goods. The combined effect of the stronger revenue and margins is expected to result in a material increase in adjusted EBITDA over the prior year (2025: £7.3m) with adjusted EBITDA also materially ahead of market expectations.¹ The final outcome for the full year will be subject to the usual audit process, including the customary assessment of balance sheet provisioning.

The Company expects to report its audited full year results in early July.

¹ The consensus market expectations for revenue and adjusted EBITDA for the year ending 31 March 2026 are £83.5m and £7.6m respectively.

-Ends-

Contacts

ECO Animal Health Group plc

David Hallas (Chief Executive Officer)

Christopher Wilks (Chief Financial Officer)

020 8447 8899

ICR Healthcare (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

Singer Capital Markets (Nominated Adviser & Joint Broker)

Philip Davies

Jalini Kalaravy

Samed Ethemi

020 7496 3000

Panmure Liberum (Joint Broker)

Emma Earl

Will Goode

Mark Rogers

Rupert Dearden

020 3100 2000

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin^® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END